Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tarlatamab · Imdelltra, AMG-757

Bispecific antibody · Immune activation, directed at delta-like ligand 3 (DLL3) and CD3 (CD3D) · developed by Amgen

Approved FDA, May 2024
AMGN Developer
1 Registered trials

What is Tarlatamab?

Tarlatamab-dlle is a bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting T cells to kill DLL3-expressing cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Imdelltra, AMG-757
Drug type
Bispecific antibody
Targets
delta-like ligand 3 (DLL3), CD3 (CD3D)
Mechanism
Immune activation, directed at delta-like ligand 3 (DLL3) and CD3 (CD3D)
Pathways
T-cell activation, cytokine release, apoptosis
Therapy area
Oncology
Developer
Amgen Inc (AMGN)
FDA status
Approved as Imdelltra (May 16, 2024), BLA761344 · FDA label
UNII
74X82ST8Q1

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07005128 Phase 3 Small-cell Lung Cancer Active not recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Extensive Stage Small-cell Lung CancerSmall-cell Lung Cancer

Other drugs acting on DLL3 / CD3D

CTIM-76 Phase 1 Gocatamig Phase 1/2 Xaluritamig Phase 3 ZW171 Phase 1

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Tarlatamab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.